Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,375.08
(
-1.58%
)
US TECH 100
22,526.40
(
-1.85%
)
Dow Jones
45,211.38
(
-1.63%
)
Brent Oil
105.43
(
4.73%
)
Bitcoin
65,735.99
(
-4.43%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dangerM post# 204862

Monday, 10/03/2016 10:23:19 AM

Monday, October 03, 2016 10:23:19 AM

Post# of 257295

Endurance-3 seems to be missing—perhaps a late-breaker?

That's my hope; ENDURANCE-3 is going to be one of the most consequential trials (due to the Sovaldi/Dakilza active-control arm) for ABBV/ENTA's next-gen regimen.

who in marketing invented those names - glecaprevir (ABT-493) / pibrentasvir (ABT-530)?

At least they have the proper suffixes: "previr" for a PI, and "asvir" for an NS5A :- )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today